Oral propranolol for prevention of threshold retinopathy of prematurity (ROPROP): protocol of a randomised controlled trial

Creative Commons License

Buhrer C., ERDEVE Ö., Bassler D., Bar-Oz B.

BMJ OPEN, cilt.8, sa.7, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 8 Sayı: 7
  • Basım Tarihi: 2018
  • Doi Numarası: 10.1136/bmjopen-2018-021749
  • Dergi Adı: BMJ OPEN
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Propranolol, Retinopathy Of Prematurity, Repurposing, Randomized Controlled Trial, OXYGEN-INDUCED RETINOPATHY, BIRTH-WEIGHT INFANTS, NEONATAL MORBIDITIES, INTRAVITREAL BEVACIZUMAB, CLINICAL-TRIAL, MOUSE MODEL, RECEPTOR, EFFICACY, BLOCKADE, COUNT
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Ankara Üniversitesi Adresli: Evet

Özet

Introduction Retinopathy of prematurity (ROP) is a disease observed in extremely premature infants characterised by visioning-threatening retinal vessel proliferation. Propranolol, a drug used for decades in newborn infants with heart diseases, hypertension and thyrotoxicosis and licenced for infantile haemangiomas, may be effective in halting progression of ROP to severe stages, as suggested by preliminary data from small studies.